Clinical Trial Update: Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral ibrutinib for respiratory failure due to COVID-19 has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronavirus Induced Disease-2019

Drugs mentioned

• Ibrutinib (ibrutinib)

Snippet

Sponsor: AbbVie | Conditions: CoronaVirus Induced Disease-2019 (COVID-19) | Phase 2 | Status: COMPLETED | Results posted: 2022-06-01